Quirós, L.P. and Ugalde, R. 2019. Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund. Global and Regional Health Technology Assessment. 6, 1 (Mar. 2019). DOI:https://doi.org/10.33393/grhta.2019.467.